These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18032505)

  • 1. Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.
    Gros L; Pelegrin M; Michaud HA; Bianco S; Hernandez J; Jacquet C; Piechaczyk M
    J Virol; 2008 Feb; 82(3):1339-49. PubMed ID: 18032505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.
    Michaud HA; Gomard T; Gros L; Thiolon K; Nasser R; Jacquet C; Hernandez J; Piechaczyk M; Pelegrin M
    PLoS Pathog; 2010 Jun; 6(6):e1000948. PubMed ID: 20548955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy.
    Gros L; Pelegrin M; Plays M; Piechaczyk M
    J Virol; 2006 Oct; 80(20):10191-200. PubMed ID: 17005696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.
    Nasser R; Pelegrin M; Michaud HA; Plays M; Piechaczyk M; Gros L
    J Virol; 2010 Oct; 84(19):10169-81. PubMed ID: 20610721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.
    Gros L; Dreja H; Fiser AL; Plays M; Pelegrin M; Piechaczyk M
    J Virol; 2005 May; 79(10):6272-80. PubMed ID: 15858011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies.
    Nasser R; Pelegrin M; Plays M; Gros L; Piechaczyk M
    Blood; 2013 Feb; 121(7):1102-11. PubMed ID: 23264590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization.
    Seiler P; Bründler MA; Zimmermann C; Weibel D; Bruns M; Hengartner H; Zinkernagel RM
    J Exp Med; 1998 Feb; 187(4):649-54. PubMed ID: 9463415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.
    Iseda S; Takahashi N; Poplimont H; Nomura T; Seki S; Nakane T; Nakamura M; Shi S; Ishii H; Furukawa S; Harada S; Naruse TK; Kimura A; Matano T; Yamamoto H
    J Virol; 2016 Jul; 90(14):6276-6290. PubMed ID: 27122584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71.
    Deng YQ; Ma J; Xu LJ; Li YX; Zhao H; Han JF; Tao J; Li XF; Zhu SY; Qin ED; Qin CF
    Appl Microbiol Biotechnol; 2015 Sep; 99(18):7663-71. PubMed ID: 25967656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.
    Neal ZC; Splitter GA
    J Virol; 1995 Aug; 69(8):4914-23. PubMed ID: 7609060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.
    Kreil TR; Maier E; Fraiss S; Eibl MM
    J Virol; 1998 Apr; 72(4):3076-81. PubMed ID: 9525632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.
    Naranjo-Gomez M; Lambour J; Piechaczyk M; Pelegrin M
    JCI Insight; 2018 May; 3(9):. PubMed ID: 29720574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
    Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J
    Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.
    Pincus SH; Cole R; Ireland R; McAtee F; Fujisawa R; Portis J
    J Virol; 1995 Nov; 69(11):7152-8. PubMed ID: 7474136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.
    Neal ZC; Splitter GA
    J Virol; 1998 Oct; 72(10):8052-60. PubMed ID: 9733845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins.
    Kyburz D; Speiser DE; Battegay M; Hengartner H; Zinkernagel RM
    Eur J Immunol; 1993 Jul; 23(7):1540-5. PubMed ID: 8325330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells.
    Battegay M; Moskophidis D; Waldner H; Bründler MA; Fung-Leung WP; Mak TW; Hengartner H; Zinkernagel RM
    J Immunol; 1993 Nov; 151(10):5408-15. PubMed ID: 7693811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells.
    Murali-Krishna K; Ravi V; Manjunath R
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():705-14. PubMed ID: 8627259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV).
    Rosato A; Mandruzzato S; Bronte V; Zambon A; Macino B; Calderazzo F; Zanovello P; Collavo D
    Int J Cancer; 1995 May; 61(3):355-62. PubMed ID: 7729948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.